MATRITECH PLANS JUNE PMA FOR URINE-BASED IVD FOR BLADDER CANCER
This article was originally published in The Gray Sheet
Executive Summary
MATRITECH PLANS JUNE PMA FOR URINE-BASED IVD FOR BLADDER CANCER utilizing the company's proprietary nuclear matrix protein technology. The company is nearing completion of clinicals evaluating the enzyme immunoassay diagnostic kit in over 1,000 patients at 16 U.S. sites.